Roche Holding Ltd · SIX:RO
Roche — Investor Presentation (2022)
11 slides from Roche's investor presentation, 2022
Slide 1: Roche and Genentech Company Presentation
Roche and Genentech Company Presentation Pharma Partnering 2022
Slide 2: The Roche Group
The Roche Group A leading healthcare company dedicated to innovation in a sustainable way 1896 Genentech1, first Founded in Basel, 62.8 bn publicly-owned family still holds majority stake Sales 2021 (CHF) Biotech ♯1 16,400,000 R&D investor in 100,920 people treated Employees worldwide worldwide with
Slide 3: Our unique innovation model
Our unique innovation model Providing scientific freedom to work, think and address problems in different ways v RESEARCH AND EARLY DEVELOPMENT LATE STAGE AND COMMERCIAL (PHARMA) gRED Global Product Development pRED Manufacturing Chugai Commercialization Independent Centers for Research and Early De
Slide 4: The leader in personalized healthcare
The leader in personalized healthcare Optimally positioning us for the future Combining pharmaceuticals and diagnostics under one roof together with deep know-how in molecular biology and data science, makes Roche a unique partner to drive the next step in the evolution of healthcare. Leader in Diag
Slide 5: Global presence
Global presence Pharma Partnering offices Cambridge Basel Boston Tokyo With around 120 people South San Shanghai Francisco worldwide, Pharma Partnering offers speed, flexibility and accessibility to partners.
Slide 6: Because a great idea is a great idea… …no matter where it comes from
Because a great idea is a great idea… …no matter where it comes from ∼ 50% ∼ 40% of R&D pipeline of total Pharma involve a partnership sales generated from partnered or in-licensed products
Slide 7: We make medicines for people with serious diseases
We make medicines for people with serious diseases 1896 1976 1987 1993 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2006 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
Slide 8: Bringing early external innovation successfully to patients
Bringing early external innovation successfully to patients >2/3 of the partnered and launched medicines were partnered pre-clinical-Phase 1 Dev. stage at deal signing Commercial Phase 3 Phase 2 Phase 1 2 Pre-Clinical 3 Launch Year1 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 1 first laun
Slide 9: Our approach to partnering in the pharma industry
Our approach to partnering in the pharma industry We value external innovation and bring our best experts to the table OUR FOUR STEP PARTNERING PROCESS Identify Search Start Ensure the areas of interest for the latest the first conversations an enduring partnership developments
Slide 10: We value external innovation
We value external innovation Complementing our internal innovation and expertise 8 1 AGREEMENTS ENTERED IN: Product out-licensing agreements Acquisition and divestments ■ Oncology ■ Immunology 60 ■ Ophthalmology 9 NEW AGREEMENTS 15 Agreements derived from in 2021 Product, technology or ■ Gene therap
Slide 11: Get in touch with us!
Get in touch with us! roche.com/partnering [email protected]